How antibodies block HIV infection: paths to an AIDS vaccine.
We are beginning to understand the mechanism that envelope proteins of the human and simian immunodeficiency viruses use to gain entry into host cells. A vaccine that can elicit antibodies that bind to the viral epitopes involved in this process would thereby prevent HIV infection. This article outlines our progress in the development of possible candidates for AIDS vaccines.
S
S
Putney
D016915:AIDS Vaccines / Q000276:immunology*; D000595:Amino Acid Sequence; D000818:Animals; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D015686:Gene Products, env / Q000276:immunology; D015483:HIV Antibodies / Q000276:immunology*; D015699:HIV Envelope Protein gp120 / Q000276:immunology; D019302:HIV Envelope Protein gp160; D015658:HIV Infections / Q000517:prevention & control*; D015497:HIV-1 / Q000276:immunology / Q000502:physiology; D006801:Humans; D008969:Molecular Sequence Data; D009500:Neutralization Tests; D011498:Protein Precursors / Q000276:immunology; D015302:Simian Immunodeficiency Virus / Q000276:immunology
D016915:AIDS Vaccines; D015686:Gene Products, env; D015483:HIV Antibodies; D015699:HIV Envelope Protein gp120; D019302:HIV Envelope Protein gp160; D011498:Protein Precursors